140 related articles for article (PubMed ID: 11710686)
1. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
2. The mind's eye.
Asa SL; Cheung CC
Am J Clin Pathol; 2001 Nov; 116(5):635-6. PubMed ID: 11710678
[No Abstract] [Full Text] [Related]
3. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
4. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
5. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
Scognamiglio T; Hyjek E; Kao J; Chen YT
Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
11. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
13. Hyalinizing trabecular adenoma of the thyroid revisited: a histologic and immunohistochemical study of thyroid lesions with prominent trabecular architecture and sclerosis.
Galgano MT; Mills SE; Stelow EB
Am J Surg Pathol; 2006 Oct; 30(10):1269-73. PubMed ID: 17001158
[TBL] [Abstract][Full Text] [Related]
14. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
15. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
18. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
[TBL] [Abstract][Full Text] [Related]
19. [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
Laco J; Ryska A
Cesk Patol; 2006 Jul; 42(3):120-4. PubMed ID: 16955558
[TBL] [Abstract][Full Text] [Related]
20. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]